{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:53:57Z","timestamp":1782161637325,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010950","name":"Department of Science and Technology of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ibroneuroreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IBRO Neuroscience Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ibneur.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:50:05Z","timestamp":1772484605000},"page":"457-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structural and functional magnetic resonance imaging abnormalities and plasma GLP-1 levels in Parkinson's disease\u00a0with cognitive impairment"],"prefix":"10.1016","volume":"20","author":[{"given":"Yunfei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghan","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ibneur.2026.02.018_bib1","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.ibneur.2026.02.018_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00415-014-7591-5","article-title":"Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease","volume":"262","author":"Amboni","year":"2015","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ibneur.2026.02.018_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuroimage.2007.07.007","article-title":"A fast diffeomorphic image registration algorithm","volume":"38","author":"Ashburner","year":"2007","journal-title":"NeuroImage"},{"issue":"6","key":"10.1016\/j.ibneur.2026.02.018_bib4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1006\/nimg.2000.0582","article-title":"Voxel-based morphometry\u2014the methods","volume":"11","author":"Ashburner","year":"2000","journal-title":"NeuroImage"},{"issue":"10291","key":"10.1016\/j.ibneur.2026.02.018_bib5","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ibneur.2026.02.018_bib6","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson\u2019s disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ibneur.2026.02.018_bib7","first-page":"775","article-title":"The association between type 2 diabetes mellitus and Parkinson\u2019s disease","volume":"10","author":"Cheong","year":"2020","journal-title":"J. Park. 's. Dis."},{"issue":"11","key":"10.1016\/j.ibneur.2026.02.018_bib8","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1111\/ene.15489","article-title":"Morphometric magnetic resonance imaging cortico-subcortical features in Parkinson's disease with mild cognitive impairment","volume":"29","author":"Cicero","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"19","key":"10.1016\/j.ibneur.2026.02.018_bib9","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","article-title":"The MoCA: well-suited screen for cognitive impairment in Parkinson disease","volume":"75","author":"Dalrymple-Alford","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ibneur.2026.02.018_bib10","first-page":"401","article-title":"Clinical features, pathophysiology and treatment of dementia associated with Parkinson's disease","author":"Emre","year":"2007","journal-title":"Park. 's. Dis. Relat. Disord. Part I"},{"key":"10.1016\/j.ibneur.2026.02.018_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123283","article-title":"Optimal MMSE and MoCA cutoffs for cognitive diagnoses in Parkinson's disease: a data-driven decision tree model","volume":"466","author":"Fiorenzato","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"15","key":"10.1016\/j.ibneur.2026.02.018_bib12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ibneur.2026.02.018_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-021-00301-7","article-title":"Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson\u2019s disease","volume":"27","author":"Hirano","year":"2021","journal-title":"Mol. Med."},{"key":"10.1016\/j.ibneur.2026.02.018_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109952","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?","volume":"253","author":"H\u00f6lscher","year":"2024","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.ibneur.2026.02.018_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ibneur.2026.02.018_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.ibneur.2026.02.018_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dom.15331","article-title":"Diabetes, antidiabetic medications and risk of dementia: a systematic umbrella review and meta-analysis","volume":"26","author":"Kuate Defo","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ibneur.2026.02.018_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s12602-024-10433-x","article-title":"Gut microbiota-based interventions for parkinson\u2019s disease: neuroprotective mechanisms and current perspective","author":"Kumar","year":"2025","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"10.1016\/j.ibneur.2026.02.018_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2020.102252","article-title":"Mild behavioral impairment in Parkinson's disease is associated with altered corticostriatal connectivity","volume":"26","author":"Lang","year":"2020","journal-title":"NeuroImage Clin."},{"issue":"2","key":"10.1016\/j.ibneur.2026.02.018_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-240001","article-title":"The association of circulating glucagon-like peptide-1 with cognitive functions and biomarkers in Alzheimer\u2019s disease","volume":"99","author":"Liu","year":"2024","journal-title":"J. Alzheimer's. Dis."},{"issue":"30","key":"10.1016\/j.ibneur.2026.02.018_bib21","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1523\/JNEUROSCI.1852-08.2008","article-title":"Magnocellular pathway impairment in Schizophrenia: evidence from functional magnetic resonance imaging","volume":"28","author":"Mart\u00ednez","year":"2008","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.ibneur.2026.02.018_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2741\/e711","article-title":"Brain MRI in Parkinson's disease","volume":"6","author":"Meijer","year":"2014","journal-title":"Front. Biosci. (Elite Ed. )"},{"issue":"5","key":"10.1016\/j.ibneur.2026.02.018_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101470","article-title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","volume":"49","author":"Monney","year":"2023","journal-title":"Diabetes & Metab."},{"issue":"1","key":"10.1016\/j.ibneur.2026.02.018_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-019-0516-y","article-title":"Different memory patterns of digits: a functional MRI study","volume":"26","author":"Nie","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ibneur.2026.02.018_bib25","author":"Organization","year":"2019","journal-title":"Int. Stat. Classif. Dis. Relat. Health Probl."},{"issue":"12","key":"10.1016\/j.ibneur.2026.02.018_bib26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.ibneur.2026.02.018_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-017-0802-6","article-title":"Microbiota-brain-gut axis and neurodegenerative diseases","volume":"17","author":"Quigley","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"10","key":"10.1016\/j.ibneur.2026.02.018_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70062","article-title":"Parietal memory network and memory encoding versus retrieval impairments in PD-MCI patients: a hippocampal volume and cortical thickness study","volume":"30","author":"Sahin","year":"2024","journal-title":"CNS Neurosci. & Ther."},{"issue":"13","key":"10.1016\/j.ibneur.2026.02.018_bib29","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMe2401743","article-title":"GLP-1, Parkinson\u2019s disease, and neuroprotection","volume":"390","author":"Standaert","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ibneur.2026.02.018_bib30","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.ibneur.2026.02.018_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment","volume":"179","author":"Trapp","year":"2022","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.ibneur.2026.02.018_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3803\/EnM.2022.1642","article-title":"Glucagon-like peptide 1 therapy: from discovery to Type 2 Diabetes and Beyond","volume":"38","author":"Viljoen","year":"2023","journal-title":"Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ibneur.2026.02.018_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/brain.2012.0073","article-title":"Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks","volume":"2","author":"Whitfield-Gabrieli","year":"2012","journal-title":"Brain Connect."},{"issue":"14","key":"10.1016\/j.ibneur.2026.02.018_bib34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4103\/1673-5374.121625","article-title":"Changes of brain gray matter structure in Parkinson's disease patients with dementia","volume":"8","author":"Xia","year":"2013","journal-title":"Neural Regen. Res"},{"issue":"3","key":"10.1016\/j.ibneur.2026.02.018_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12021-016-9299-4","article-title":"DPABI: data processing & analysis for (resting-state) brain imaging","volume":"14","author":"Yan","year":"2016","journal-title":"Neuroinformatics"},{"issue":"2","key":"10.1016\/j.ibneur.2026.02.018_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bdi.12966","article-title":"Altered cerebral perfusion in bipolar disorder: a pCASL MRI study","volume":"23","author":"Zeng","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.ibneur.2026.02.018_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.media.2022.102681","article-title":"From sMRI to task-fMRI: a unified geometric deep learning framework for cross-modal brain anatomo-functional mapping","volume":"83","author":"Zhu","year":"2023","journal-title":"Med. Image Anal."}],"container-title":["IBRO Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242126000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242126000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:18:06Z","timestamp":1782159486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667242126000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S2667242126000357"],"URL":"https:\/\/doi.org\/10.1016\/j.ibneur.2026.02.018","relation":{},"ISSN":["2667-2421"],"issn-type":[{"value":"2667-2421","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural and functional magnetic resonance imaging abnormalities and plasma GLP-1 levels in Parkinson's disease\u00a0with cognitive impairment","name":"articletitle","label":"Article Title"},{"value":"IBRO Neuroscience Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ibneur.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Brain Research Organization.","name":"copyright","label":"Copyright"}]}}